Journal
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
Volume 13, Issue 9, Pages 1163-1171Publisher
IVYSPRING INT PUBL
DOI: 10.7150/ijbs.20792
Keywords
Breast cancer; FGFR2; mutation; polymorphism; inhibitor
Categories
Funding
- Chair Professor Grant [CPG2017-00026-FHS]
- Startup Research Grant [SRG2015-00045-FHS]
- University of Macau [MYRG2016-00132-FHS, MYRG2016-00139]
- FDCT [065/2015/A2, 094/2015/A3]
- University of Macau, SAR. China
Ask authors/readers for more resources
Fibroblast growth factor receptor 2 (FGFR2) is a membrane-spanning tyrosine kinase that mediates signaling for FGFs. Recent studies detected various point mutations of FGFR2 in multiple types of cancers, including breast cancer, lung cancer, gastric cancer, uterine cancer and ovarian cancer, yet the casual relationship between these mutations and tumorigenesis is unclear. Here we will discuss possible interactions between FGFR2 signaling and several major pathways through which the aberrantly activated FGFR2 signaling may result in breast cancer development. We will also discuss some recent developments in the discovery and application of therapies and strategies for breast cancers by inhibiting FGFR2 activities.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available